ResultsIQ

ResultsIQ › Latest results › Divi's Laboratories Limited

Divi's Laboratories Limited Q1 FY26 earnings call summary

NSE: DIVISLAB · BSE: 532488

Earnings call of 6 Aug 2025, summarised by AI from the filing.

Divi's Labs Q1 FY26 consolidated revenue ₹2,529 cr, PAT ₹545 cr; FY26 capex guidance raised to ₹2,000 cr.

Key takeaways

  1. Growth driver Custom synthesis pipeline with multiple projects to commercialize in 12-24 months; peptide capacity commissioned.
  2. Main risk Pricing pressures in generics continue, impacting gross margins.

Original filing on BSE

Divi's Laboratories Limited Q1 FY27 results

As filed: Revenue ₹3,080 cr (+28% year on year), EBITDA ₹1,255 cr (+72% year on year), PAT ₹902 cr (+66% year on year), EBITDA margin 40.8% (+1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹2,831 cr (+10% year on year), EBITDA ₹934 cr (+5% year on year), PAT ₹751 cr (+13% year on year), EBITDA margin 33.0% (−128 bps). Score 31 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin fell 128 bps year on year. Revenue rose ₹246 cr on a year ago, against ₹282 cr the year before. Share price after the results: −1.4% in 30 days (Nifty 500: +2.7%).
  • Q3 FY26: Revenue ₹2,604 cr (+12% year on year), EBITDA ₹890 cr (+20% year on year), PAT ₹583 cr (−1% year on year), EBITDA margin 34.2% (+214 bps). Score 28 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit growth was well below it. EBITDA margin rose 214 bps year on year. Revenue fell 4% from last quarter. Revenue rose ₹285 cr on a year ago, against ₹464 cr the year before. Share price after the results: −1.7% in 30 days (Nifty 500: −9.9%).
  • Q2 FY26: Revenue ₹2,715 cr (+16% year on year), EBITDA ₹888 cr (+24% year on year), PAT ₹689 cr (+35% year on year), EBITDA margin 32.7% (+208 bps). Score 44 of 100, In line with trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was below it. EBITDA margin rose 208 bps year on year. Profit rose ₹179 cr on a year ago, more than the ₹162 cr it added the year before. Share price after the results: −2.7% in 28 days (Nifty 500: +1.3%).
  • Q1 FY26: Revenue ₹2,410 cr (+14% year on year), EBITDA ₹729 cr (+17% year on year), PAT ₹545 cr (+27% year on year), EBITDA margin 30.3% (+88 bps). Score 48 of 100, In line with trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin rose 88 bps year on year. Revenue fell 7% from last quarter. Revenue rose ₹292 cr on a year ago, against ₹340 cr the year before. Share price after the results: −6.2% in 30 days (Nifty 500: +0.1%).
  • Q4 FY25: Revenue ₹2,585 cr (+12% year on year), EBITDA ₹886 cr (+21% year on year), PAT ₹662 cr (+23% year on year), EBITDA margin 34.3% (+253 bps). Score 35 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin rose 253 bps year on year. Revenue rose ₹282 cr on a year ago, against ₹352 cr the year before. Share price after the results: +6.5% in 30 days (Nifty 500: +1.0%).
  • Q3 FY25: Revenue ₹2,319 cr (+25% year on year), EBITDA ₹743 cr (+52% year on year), PAT ₹589 cr (+65% year on year), EBITDA margin 32.0% (+568 bps). Score 82 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 568 bps year on year. Profit rose ₹231 cr on a year ago, more than the ₹51.0 cr it added the year before.
  • Q2 FY25: Revenue ₹2,338 cr (+22% year on year), EBITDA ₹716 cr (+49% year on year), PAT ₹510 cr (+47% year on year), EBITDA margin 30.6% (+553 bps). Score 86 of 100, Above trend. EBITDA margin rose 553 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Divi's Laboratories Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.